Superantigens, such as staphylococcal enterotoxin B (SEB), elicit a strong proliferative response in T cells when presented in the context of major histocompatibility complex (MHC) class II molecules. We observed a similar T-cell response, when MHC class II-negative epidermal cell lines were employed as antigen-presenting cells. Immunoprecipitation studies indicated that the ligand to which SEB bound had a molecular mass of 46 kDa. Radiolabeled SEB could be immunoprecipitated from isolated membrane proteins on the SCC13 epidermal cell line with a monoclonal antibody directed against the MHC class I molecule, and transfection of the K-562 cell line with MHC class I molecules showed a 75% increased SEB-binding capacity compared with the nontransfected MHC class I-and class II-negative counterpart. In functional studies, antibodies to the MHC class I molecule inhibited T-cell proliferation by at least 50%. From these studies, we conclude that MHC class I molecules on malignant squamous cell carcinomas serve as ligands for SEB, which, given the appropriate costimulatory signals, is sufficient to allow for superantigen-induced T-cell proliferation.
Superantigens are a heterogeneous group of structurally diverse bacterial exotoxins, viral protein products, and endogenous self-antigens that include staphylococcal exotoxins A-E, toxic shock syndrome toxin, streptococcal pyrogenic toxins, and protein products of Mycoplasma arthritidis and the human immunodeficiency virus (1, 2) . They are key participants in a variety of diseases and have been implicated in the pathogenesis of such chronic cutaneous disorders as atopic dermatitis and psoriasis (3, 4) .
The precise mechanism by which superantigens cause these diseases is still incompletely understood, although much attention has focused on their ability to activate subpopulations of T lymphocytes that bear specific V3B T-cell antigen receptors (TCRs carrying a specific (3-chain variable region) (1, (5) (6) (7) . This activation process initiates T-cell proliferation and cytokine production (8, 9) and confers non-MHC specific T-cell cytotoxicity against a variety of tumor lines (6, 10, 11) . Like conventional antigens, superantigens require antigen-presenting cells (APC) for optimal T-cell activation. In most situations, these potent T-cell stimuli bind to APC through covalent interactions with MHC class II determinants. However, unlike conventional antigens, superantigens adhere to nonpolymorphic regions on the outer face of the molecule rather than to the antigen-binding groove (12, 13) . This unique interaction enables APC to bypass the usual MHC haplotype restrictions for T-cell activation.
The relationship between superantigens and class II MHC is well established and, with respect to SEB, has recently been confirmed by x-ray crystallography (14, 15) . However, observations in our laboratory (vide infra) and reports by other
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groups (16) (17) (18) (19) strongly suggest that ligands aside from MHC class II molecules exist on APC. This is of particular interest because many of the superantigen-presenting cells used to demonstrate MHC class II-independent T-cell activation are tumor cell lines (17) (18) (19) . tTo whom reprint requests should be addressed.
culture medium). Cultures were fed twice a week and maintained at 37°C in 5% C02/95% air. T-lymphocytes were isolated by a four-step purification procedure that has been described (20 (Fig. 2) . It should be noted, however, that pretreatment of cultured keratinocytes with interferon y, allowed them to present SEB to T cells (Fig. 2) , confirming the findings of other investigators (21) .
A distinguishing characteristic of the T-cell-activating properties of superantigens is their ability to selectively activate specific subpopulations of T cells that express appropriate Vp-encoded elements on their T-cell receptor (1) . In humans, the major V/3 TCR family activated by SEB is V133, whereas the toxic shock syndrome toxin (TSST-1) is proficient at activating T cells that express the V132 TCR (22, 23) . To prove that the T-cell proliferative response in this system was truly SEBmediated, an assessment of the percentage of cells expressing the V32 and V133 TCRs was made. The percentage of T cells (Fig. 5, lanes 3 and 4) . Because (Fig. 3 Right) . A similar inhibitory effect of anti-class I antibodies was observed when paraformaldehyde-fixed SCC13 cells were preincubated with the antibody, washed, and then placed in culture with T cells and SEB (Fig. 4) .
To assess the role of the adhesion molecules ICAM-1 and B7 in this system, purified neutralizing mAbs to those molecules were added to proliferation assays. [3H]Thymidine uptake was inhibited by 60-70% in the presence of anti-ICAM-1 antibodies, whereas antibodies directed against B7 had little or no effect on T-cell proliferation (Fig. 7) . It should be noted that the anti-B7 antibody we employed can bind to epidermal tumor cell lines (24) (1, (25) (26) (27) (32) (33) (34) (35) (36) and that this interaction plays a key role in T-cell activation. While not to deny its significance, several studies cast doubt that it is the only molecular pathway that allows T-cell activation to proceed. For example, staphylococcal enterotoxin A (SEA)-and SEB-induced lymphocyte activation can occur when class II-negative colon carcinoma cell lines are used as APC (37, 38) . Moreover, MHC class II negative "knockout" mice retain their ability to elicit a T-cell proliferative response to selected staphylococcal enterotoxins (39) In contrast to our findings in various squamous cell carcinomas lines (SCC13, SCC4, and A431), normal keratinocytes have been shown to be poor APC for SEB (21, 40 (41, 42) and B7 (43, 44) have been shown to be critical costimulatory signals in T-cell-target cell interactions. In our experiments, neutralizing antibodies to ICAM-1 had a substantial inhibitory effect on SEB-induced T-cell proliferation in our system. SCC13 cells and other malignant epidermal cell lines strongly express ICAM-1 on their surface (45, 46 
